JP2022521764A5 - - Google Patents
Info
- Publication number
- JP2022521764A5 JP2022521764A5 JP2021549698A JP2021549698A JP2022521764A5 JP 2022521764 A5 JP2022521764 A5 JP 2022521764A5 JP 2021549698 A JP2021549698 A JP 2021549698A JP 2021549698 A JP2021549698 A JP 2021549698A JP 2022521764 A5 JP2022521764 A5 JP 2022521764A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- molecule
- grna
- rho
- acid according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962810320P | 2019-02-25 | 2019-02-25 | |
| US62/810,320 | 2019-02-25 | ||
| PCT/US2020/019766 WO2020176552A1 (en) | 2019-02-25 | 2020-02-25 | Crispr/rna-guided nuclease-related methods and compositions for treating rho-associated autosomal-dominant retinitis pigmentosa (adrp) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022521764A JP2022521764A (ja) | 2022-04-12 |
| JP2022521764A5 true JP2022521764A5 (enExample) | 2023-03-07 |
Family
ID=69960739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021549698A Pending JP2022521764A (ja) | 2019-02-25 | 2020-02-25 | Ｒｈｏ関連常染色体優性網膜色素変性症（ａｄｒｐ）を治療するためのｃｒｉｓｐｒ／ｒｎａ誘導ヌクレアーゼ関連の方法及び組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220133768A1 (enExample) |
| EP (1) | EP3931326A1 (enExample) |
| JP (1) | JP2022521764A (enExample) |
| KR (1) | KR20210133993A (enExample) |
| CN (1) | CN113631710A (enExample) |
| AU (1) | AU2020227740A1 (enExample) |
| CA (1) | CA3130515A1 (enExample) |
| IL (1) | IL285680A (enExample) |
| WO (1) | WO2020176552A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3119301A1 (en) * | 2018-11-08 | 2020-05-14 | National University Corporation Tokai National Higher Education And Research System | Gene therapy employing genome editing with single aav vector |
| WO2021122944A1 (en) * | 2019-12-18 | 2021-06-24 | Alia Therapeutics Srl | Compositions and methods for treating retinitis pigmentosa |
| WO2022094363A1 (en) * | 2020-11-01 | 2022-05-05 | University of South Alabama Foundation for Research and Commercialization | Barcoded cells engineered with heterozygous genetic diversity |
| WO2022221741A1 (en) * | 2021-04-16 | 2022-10-20 | Editas Medicine, Inc. | Crispr/rna-guided nuclease-related methods and compositions for treating rho-associated autosomal-dominant retinitis pigmentosa (adrp) |
| WO2023285431A1 (en) * | 2021-07-12 | 2023-01-19 | Alia Therapeutics Srl | Compositions and methods for allele specific treatment of retinitis pigmentosa |
| AU2023326046A1 (en) * | 2022-08-16 | 2025-02-20 | Adelaide university | Agent for treating or preventing a dominantly-inherited disease |
| CA3267752A1 (en) * | 2022-09-16 | 2024-03-21 | Alia Therapeutics Srl | ENQP TYPE II CAS PROTEINS AND THEIR APPLICATIONS |
| EP4590819A2 (en) * | 2022-09-20 | 2025-07-30 | The Board of Trustees of the Leland Stanford Junior University | Methods and compositions to control gene using genome editing |
| CN116555259B (zh) * | 2023-04-20 | 2024-02-27 | 云舟生物科技(广州)股份有限公司 | 核酸分子及其作为启动子的应用 |
| WO2025090637A2 (en) * | 2023-10-23 | 2025-05-01 | Prime Medicine, Inc. | Genome editing compositions and methods for treatment of retinitis pigmentosa |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5443505A (en) | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
| US5725493A (en) | 1994-12-12 | 1998-03-10 | Avery; Robert Logan | Intravitreal medicine delivery |
| US6299895B1 (en) | 1997-03-24 | 2001-10-09 | Neurotech S.A. | Device and method for treating ophthalmic diseases |
| CA2383499C (en) | 1999-10-21 | 2009-11-24 | Alcon Universal Ltd. | Drug delivery device |
| US6416777B1 (en) | 1999-10-21 | 2002-07-09 | Alcon Universal Ltd. | Ophthalmic drug delivery device |
| JP7103750B2 (ja) * | 2013-12-12 | 2022-07-20 | ザ・ブロード・インスティテュート・インコーポレイテッド | ゲノム編集のためのＣＲＩＳＰＲ－Ｃａｓ系及び組成物の送達、使用及び治療適用 |
| US11028388B2 (en) | 2014-03-05 | 2021-06-08 | Editas Medicine, Inc. | CRISPR/Cas-related methods and compositions for treating Usher syndrome and retinitis pigmentosa |
| WO2015188056A1 (en) * | 2014-06-05 | 2015-12-10 | Sangamo Biosciences, Inc. | Methods and compositions for nuclease design |
| ES2788426T3 (es) * | 2014-06-16 | 2020-10-21 | Univ Johns Hopkins | Composiciones y métodos para la expresión de ARNs de guía de CRISPR utilizando el promotor de H1 |
| US20160324987A1 (en) * | 2015-04-15 | 2016-11-10 | Cedars-Sinai Medical Center | Use of crispr/cas9 as in vivo gene therapy to generate targeted genomic disruptions in genes bearing dominant mutations for retinitis pigmentosa |
| EP3289080B1 (en) * | 2015-04-30 | 2021-08-25 | The Trustees of Columbia University in the City of New York | Gene therapy for autosomal dominant diseases |
| US11512311B2 (en) | 2016-03-25 | 2022-11-29 | Editas Medicine, Inc. | Systems and methods for treating alpha 1-antitrypsin (A1AT) deficiency |
| KR20190039703A (ko) * | 2016-07-05 | 2019-04-15 | 더 존스 홉킨스 유니버시티 | Crispr/cas9-기반 조성물 및 망막 변성을 치료하기 위한 방법 |
| CN110168084A (zh) | 2016-12-05 | 2019-08-23 | 爱迪塔斯医药公司 | 用于内源和来源DNA的单发指导RNA(ogRNA)靶向的系统和方法 |
| EP3622070A2 (en) * | 2017-05-10 | 2020-03-18 | Editas Medicine, Inc. | Crispr/rna-guided nuclease systems and methods |
| CA3082450A1 (en) * | 2017-11-21 | 2019-05-31 | Crispr Therapeutics Ag | Materials and methods for treatment of autosomal dominant retinitis pigmentosa |
| CN112153990A (zh) * | 2018-03-23 | 2020-12-29 | 纽约市哥伦比亚大学理事会 | 用于常染色体显性疾病的基因编辑 |
-
2020
- 2020-02-25 CA CA3130515A patent/CA3130515A1/en active Pending
- 2020-02-25 AU AU2020227740A patent/AU2020227740A1/en not_active Abandoned
- 2020-02-25 WO PCT/US2020/019766 patent/WO2020176552A1/en not_active Ceased
- 2020-02-25 EP EP20714062.5A patent/EP3931326A1/en active Pending
- 2020-02-25 CN CN202080025160.5A patent/CN113631710A/zh active Pending
- 2020-02-25 US US17/433,975 patent/US20220133768A1/en active Pending
- 2020-02-25 KR KR1020217030652A patent/KR20210133993A/ko active Pending
- 2020-02-25 JP JP2021549698A patent/JP2022521764A/ja active Pending
-
2021
- 2021-08-17 IL IL285680A patent/IL285680A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022521764A5 (enExample) | ||
| AU2022201038B2 (en) | Compositions and methods for promoting homology directed repair | |
| JP6799058B2 (ja) | アレル選択的な遺伝子編集およびその使用 | |
| JP2025118716A (ja) | ハプロ不全のための遺伝子治療 | |
| JP7844582B2 (ja) | 遺伝子編集されたｃｄ３４＋細胞におけるｆｏｘｐ３の発現 | |
| KR102501980B1 (ko) | 화학적으로 변형된 단일 가닥 rna-편집 올리고뉴클레오타이드 | |
| CA2968336C (en) | Construct for site directed editing of an adenosine nucleotide in target rna | |
| AU2021232005A1 (en) | Methods and compositions for modulating a genome | |
| TW202136508A (zh) | 用於編輯目標rna之附加有功能性領域之反義型嚮導rna | |
| RU2767201C2 (ru) | Искусственная модификация генома для регуляции экспрессии гена | |
| JP2017522005A (ja) | ハンチントン病の治療化合物 | |
| AU2018241847A1 (en) | Diaphragm-specific nucleic acid regulatory elements and methods and use thereof | |
| JP7350361B2 (ja) | 遺伝子改変細胞をポジティブに選択して、排除するための短ヘアピンｒｎａ（ｓｈｒｎａ７３４）およびその使用 | |
| JP2026009889A (ja) | エンジニアリングされたＣａｓ１２ｉヌクレアーゼ、エフェクタータンパク質及びその用途 | |
| CA3147643A1 (en) | Compositions and methods for modulating hepatocyte nuclear factor 4-alpha (hnf4.alpha.) gene expression | |
| WO2020165603A1 (en) | Myc, cyclin t1 and/or cdk9 for use in the treatment of degenerative heart and cns disorders | |
| CN116171160A (zh) | 用于治疗代谢综合征的组合物和方法 | |
| JP2020517270A (ja) | ウィスコット・アルドリッチ症候群およびｘ連鎖性血小板減少症の治療的ゲノム編集 | |
| JP2022507283A (ja) | 脊髄小脳失調症３型の治療のためのアタキシン－３のｒｎａｉ誘導低減 | |
| EP4347821A1 (en) | Engineered guide rnas and polynucleotides | |
| CN113994009A (zh) | 用于修饰scn9a或scn10a基因的基因编辑系统及其使用方法 | |
| JP2025535495A (ja) | 遺伝子編集システムとその応用 | |
| WO2023220719A2 (en) | Method for treatment of myotonic dystrophy combining protein expression and rna interference vector delivery with tissue detargeting | |
| CA3255304A1 (en) | Methods of treating, ameliorating and/or preventing polycystic kidney disease and polycystic liver disease | |
| JP2022525528A (ja) | 細胞の遺伝子改変のための発現構築物 |